Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twelve-month randomized, double-blind, placebo-controlled trial-Reference-Cited by-同舟云学术

Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twelve-month randomized, double-blind, placebo-controlled trial

Published:2005-01 Issue:1 Volume:52 Page:27-35
ISSN:0004-3591
Container-title:Arthritis & Rheumatism
language:en
Short-container-title:Arthritis Rheum

Author:

Quinn Mark A.,Conaghan Philip G.,O'Connor Philip J.,Karim Zunaid,Greenstein Adam,Brown Andrew,Brown Clare,Fraser Alexander,Jarret Stephen,Emery Paul

Publisher

Wiley

Subject

Pharmacology (medical),Immunology,Rheumatology,Immunology and Allergy

Reference31 articles.

1. Early rheumatoid arthritis: time to aim for remission?

2. The therapeutic approach of early intervention for rheumatoid arthritis: what is the evidence?

3. Understanding the window of opportunity concept in early rheumatoid arthritis

Cited by 470 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimizing withdrawal strategies for anti-TNF-α therapies in rheumatoid arthritis;Expert Opinion on Biological Therapy;2024-07-25

2. Evaluation of Crohn's Disease Recurrence after Suspension of Immunobiological use in Patients in Sustained Remission;Journal of Coloproctology;2024-06

3. Initial Treatment with Biological Therapy in Rheumatoid Arthritis;Journal of Clinical Medicine;2023-12-21

4. Prevalence and predictors of sustained remission/low disease activity after discontinuation of induction or maintenance treatment with tumor necrosis factor inhibitors in rheumatoid arthritis: a systematic and scoping review;Arthritis Research & Therapy;2023-11-20

5. Sustained remission following the discontinuation of tofacitinib in patients with rheumatoid arthritis (XANADU study): an open-label randomised study;RMD Open;2023-04